PCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pacira BioSciences's change in inventory for the quarter that ended in Sep. 2024 was $-8.4 Mil. It means Pacira BioSciences's inventory increased by $8.4 Mil from Jun. 2024 to Sep. 2024 .
Pacira BioSciences's change in inventory for the fiscal year that ended in Dec. 2023 was $-8.3 Mil. It means Pacira BioSciences's inventory increased by $8.3 Mil from Dec. 2022 to Dec. 2023 .
Pacira BioSciences's Total Inventories for the quarter that ended in Sep. 2024 was $111.9 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Pacira BioSciences's Days Inventory for the quarter that ended in Sep. 2024 was 252.76.
Inventory Turnover measures how fast the company turns over its inventory within a year. Pacira BioSciences's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.36.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Pacira BioSciences's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.64.
The historical data trend for Pacira BioSciences's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | -8.03 | -6.35 | -4.47 | 2.49 | -8.29 |
Pacira BioSciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Change In Inventory | Get a 7-Day Free Trial | -4.39 | -7.83 | 7.57 | -6.66 | -8.43 |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (NAS:PCRX) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pacira BioSciences's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 107.6515 | / | 38.864 | * | 365 / 4 | |
= | 252.76 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pacira BioSciences's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 38.864 | / | 107.6515 | |
= | 0.36 |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacira BioSciences's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 107.6515 | / | 168.573 | |
= | 0.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pacira BioSciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Daryl Gaugler | officer: Chief Operating Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Marcelo Bigal | director | C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Michael J. Yang | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Mark Froimson | director | 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Jonathan Slonin | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Kristen Marie Williams | officer: CAO and General Counsel | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Paul J Hastings | director | 61 HARTFORD STREET, SAN FRANCISCO CA 94114 |
Lauren Bullaro Riker | officer: Executive Director, Accounting | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Gary W Pace | director | C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
Alethia Young | director | C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Abraham Ceesay | director | C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
Roy Winston | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Mark A. Kronenfeld | director | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054 |
Reinhart Charles A. Iii | officer: Chief Financial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
From GuruFocus
By GuruFocus Research • 07-31-2024
By Marketwired • 09-09-2024
By Marketwired • 10-21-2024
By Marketwired • 07-30-2024
By Marketwired • 10-07-2024
By GuruFocus News • 11-06-2024
By GuruFocus Research • 09-16-2024
By Marketwired • 07-10-2024
By GuruFocus News • 12-03-2024
By GuruFocus Research • 09-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.